724.76 USD
+11.41 (+1.6%)
712 USD
-12.76 (-1.76%)
We assign a fundamental rating of 7 out of 10 to IDXX. IDXX was compared to 185 industry peers in the Health Care Equipment & Supplies industry. IDXX has outstanding health and profitabily ratings, belonging to the best of the industry. This is a solid base for any company. IDXX has a decent growth rate and is not valued too expensively. These ratings could make IDXX a good candidate for quality investing.
1. Profitability
1.1 Basic Checks
In the past year IDXX was profitable.
IDXX had a positive operating cash flow in the past year.
IDXX had positive earnings in each of the past 5 years.
In the past 5 years IDXX always reported a positive cash flow from operatings.
1.2 Ratios
IDXX has a better Return On Assets (30.34%) than 100.00% of its industry peers.
The Return On Equity of IDXX (65.81%) is better than 100.00% of its industry peers.
IDXX's Return On Invested Capital of 40.25% is amongst the best of the industry. IDXX outperforms 100.00% of its industry peers.
Measured over the past 3 years, the Average Return On Invested Capital for IDXX is significantly above the industry average of 8.84%.
The 3 year average ROIC (35.08%) for IDXX is below the current ROIC(40.25%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROIC | 40.25% |
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
1.3 Margins
With an excellent Profit Margin value of 24.65%, IDXX belongs to the best of the industry, outperforming 95.14% of the companies in the same industry.
In the last couple of years the Profit Margin of IDXX has grown nicely.
IDXX's Operating Margin of 31.34% is amongst the best of the industry. IDXX outperforms 98.92% of its industry peers.
In the last couple of years the Operating Margin of IDXX has grown nicely.
The Gross Margin of IDXX (61.72%) is better than 63.24% of its industry peers.
In the last couple of years the Gross Margin of IDXX has remained more or less at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% |
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
2. Health
2.1 Basic Checks
With a Return on Invested Capital (ROIC) well above the Cost of Capital (WACC), IDXX is creating value.
The number of shares outstanding for IDXX has been reduced compared to 1 year ago.
Compared to 5 years ago, IDXX has less shares outstanding
IDXX has a better debt/assets ratio than last year.
2.2 Solvency
IDXX has an Altman-Z score of 24.14. This indicates that IDXX is financially healthy and has little risk of bankruptcy at the moment.
With an excellent Altman-Z score value of 24.14, IDXX belongs to the best of the industry, outperforming 96.76% of the companies in the same industry.
IDXX has a debt to FCF ratio of 1.04. This is a very positive value and a sign of high solvency as it would only need 1.04 years to pay back of all of its debts.
IDXX's Debt to FCF ratio of 1.04 is amongst the best of the industry. IDXX outperforms 90.81% of its industry peers.
IDXX has a Debt/Equity ratio of 0.53. This is a neutral value indicating IDXX is somewhat dependend on debt financing.
With a Debt to Equity ratio value of 0.53, IDXX perfoms like the industry average, outperforming 40.54% of the companies in the same industry.
Even though the debt/equity ratio score it not favorable for IDXX, it has very limited outstanding debt, so we won't put too much weight on the DE evaluation.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Altman-Z | 24.14 |
ROIC/WACC3.9
WACC10.32%
2.3 Liquidity
A Current Ratio of 1.18 indicates that IDXX should not have too much problems paying its short term obligations.
IDXX has a worse Current ratio (1.18) than 82.16% of its industry peers.
A Quick Ratio of 0.87 indicates that IDXX may have some problems paying its short term obligations.
IDXX has a Quick ratio of 0.87. This is amonst the worse of the industry: IDXX underperforms 80.54% of its industry peers.
The current and quick ratio evaluation for IDXX is rather negative, while it does have excellent solvency and profitability. These ratios do not necessarly indicate liquidity issues and need to be evaluated against the specifics of the business.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 15.16% over the past year.
IDXX shows quite a strong growth in Earnings Per Share. Measured over the last years, the EPS has been growing by 18.18% yearly.
The Revenue has grown by 8.39% in the past year. This is quite good.
IDXX shows quite a strong growth in Revenue. Measured over the last years, the Revenue has been growing by 10.12% yearly.
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%
3.2 Future
The Earnings Per Share is expected to grow by 14.18% on average over the next years. This is quite good.
IDXX is expected to show quite a strong growth in Revenue. In the coming years, the Revenue will grow by 9.43% yearly.
EPS Next Y16.89%
EPS Next 2Y14.65%
EPS Next 3Y14.13%
EPS Next 5Y14.18%
Revenue Next Year10.46%
Revenue Next 2Y9.59%
Revenue Next 3Y9.39%
Revenue Next 5Y9.43%
3.3 Evolution
Although the future EPS growth is still strong, it is not able to hold up the even more excellent growth rate of the past years.
When comparing the Revenue growth rate of the last years to the growth rate of the upcoming years, we see that the growth is stable.
4. Valuation
4.1 Price/Earnings Ratio
The Price/Earnings ratio is 57.48, which means the current valuation is very expensive for IDXX.
Compared to the rest of the industry, the Price/Earnings ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 68.11% of the companies listed in the same industry.
When comparing the Price/Earnings ratio of IDXX to the average of the S&P500 Index (27.25), we can say IDXX is valued expensively.
Based on the Price/Forward Earnings ratio of 49.01, the valuation of IDXX can be described as expensive.
69.19% of the companies in the same industry are more expensive than IDXX, based on the Price/Forward Earnings ratio.
The average S&P500 Price/Forward Earnings ratio is at 23.98. IDXX is valued rather expensively when compared to this.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 57.48 | ||
| Fwd PE | 49.01 |
4.2 Price Multiples
Compared to the rest of the industry, the Enterprise Value to EBITDA ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 67.57% of the companies listed in the same industry.
Compared to the rest of the industry, the Price/Free Cash Flow ratio of IDXX indicates a somewhat cheap valuation: IDXX is cheaper than 71.89% of the companies listed in the same industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 61.55 | ||
| EV/EBITDA | 40.23 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates IDXX does not grow enough to justify the current Price/Earnings ratio.
The excellent profitability rating of IDXX may justify a higher PE ratio.
A more expensive valuation may be justified as IDXX's earnings are expected to grow with 14.13% in the coming years.
PEG (NY)3.4
PEG (5Y)3.16
EPS Next 2Y14.65%
EPS Next 3Y14.13%
5. Dividend
5.1 Amount
No dividends for IDXX!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
724.76
+11.41 (+1.6%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Equipment & Supplies
Earnings (Last)
Earnings (Next)
Inst Owners94.94%
Inst Owner Change0.19%
Ins Owners0.21%
Ins Owner Change2.18%
Market Cap57.87B
Revenue(TTM)4.17B
Net Income(TTM)1.03B
Analysts80.91
Price Target783.52 (8.11%)
Short Float %2.62%
Short Ratio3.62
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)7.14%
Min EPS beat(2)6.47%
Max EPS beat(2)7.81%
EPS beat(4)4
Avg EPS beat(4)5.72%
Min EPS beat(4)1.72%
Max EPS beat(4)7.81%
EPS beat(8)8
Avg EPS beat(8)4.83%
EPS beat(12)12
Avg EPS beat(12)4.67%
EPS beat(16)14
Avg EPS beat(16)4.04%
Revenue beat(2)2
Avg Revenue beat(2)1.45%
Min Revenue beat(2)1.03%
Max Revenue beat(2)1.88%
Revenue beat(4)3
Avg Revenue beat(4)0.26%
Min Revenue beat(4)-1.92%
Max Revenue beat(4)1.88%
Revenue beat(8)3
Avg Revenue beat(8)-0.81%
Revenue beat(12)3
Avg Revenue beat(12)-1.06%
Revenue beat(16)4
Avg Revenue beat(16)-1.1%
PT rev (1m)1.34%
PT rev (3m)12.82%
EPS NQ rev (1m)0.09%
EPS NQ rev (3m)1.88%
EPS NY rev (1m)-0.04%
EPS NY rev (3m)2.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.48%
Revenue NY rev (1m)0%
Revenue NY rev (3m)1.27%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 57.48 | ||
| Fwd PE | 49.01 | ||
| P/S | 13.89 | ||
| P/FCF | 61.55 | ||
| P/OCF | 53.19 | ||
| P/B | 37.07 | ||
| P/tB | 56.04 | ||
| EV/EBITDA | 40.23 |
EPS(TTM)12.61
EY1.74%
EPS(NY)14.79
Fwd EY2.04%
FCF(TTM)11.77
FCFY1.62%
OCF(TTM)13.63
OCFY1.88%
SpS52.19
BVpS19.55
TBVpS12.93
PEG (NY)3.4
PEG (5Y)3.16
Graham Number74.48
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 30.34% | ||
| ROE | 65.81% | ||
| ROCE | 61.18% | ||
| ROIC | 40.25% | ||
| ROICexc | 43.77% | ||
| ROICexgc | 56.25% | ||
| OM | 31.34% | ||
| PM (TTM) | 24.65% | ||
| GM | 61.72% | ||
| FCFM | 22.56% |
ROA(3y)25.87%
ROA(5y)26.7%
ROE(3y)74.71%
ROE(5y)84.83%
ROIC(3y)35.08%
ROIC(5y)36.07%
ROICexc(3y)39.8%
ROICexc(5y)41.54%
ROICexgc(3y)51.52%
ROICexgc(5y)54.7%
ROCE(3y)52.73%
ROCE(5y)50.92%
ROICexgc growth 3Y-5.99%
ROICexgc growth 5Y4.28%
ROICexc growth 3Y-3.86%
ROICexc growth 5Y4.07%
OM growth 3Y0.02%
OM growth 5Y4.78%
PM growth 3Y-0.56%
PM growth 5Y5.09%
GM growth 3Y1.27%
GM growth 5Y1.47%
F-Score8
Asset Turnover1.23
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0.53 | ||
| Debt/FCF | 1.04 | ||
| Debt/EBITDA | 0.57 | ||
| Cap/Depr | 105.48% | ||
| Cap/Sales | 3.55% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 75.23% | ||
| Profit Quality | 91.51% | ||
| Current Ratio | 1.18 | ||
| Quick Ratio | 0.87 | ||
| Altman-Z | 24.14 |
F-Score8
WACC10.32%
ROIC/WACC3.9
Cap/Depr(3y)119.67%
Cap/Depr(5y)117.13%
Cap/Sales(3y)3.91%
Cap/Sales(5y)3.89%
Profit Quality(3y)79.31%
Profit Quality(5y)83.23%
High Growth Momentum
Growth
EPS 1Y (TTM)15.16%
EPS 3Y9.32%
EPS 5Y18.18%
EPS Q2Q%21.43%
EPS Next Y16.89%
EPS Next 2Y14.65%
EPS Next 3Y14.13%
EPS Next 5Y14.18%
Revenue 1Y (TTM)8.39%
Revenue growth 3Y6.62%
Revenue growth 5Y10.12%
Sales Q2Q%13.29%
Revenue Next Year10.46%
Revenue Next 2Y9.59%
Revenue Next 3Y9.39%
Revenue Next 5Y9.43%
EBIT growth 1Y17.46%
EBIT growth 3Y6.64%
EBIT growth 5Y15.38%
EBIT Next Year33.04%
EBIT Next 3Y18.01%
EBIT Next 5Y15.32%
FCF growth 1Y38.31%
FCF growth 3Y7.86%
FCF growth 5Y21.3%
OCF growth 1Y31.08%
OCF growth 3Y7.13%
OCF growth 5Y15.14%
IDEXX LABORATORIES INC / IDXX FAQ
What is the ChartMill fundamental rating of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a fundamental rating of 7 / 10 to IDXX.
What is the valuation status of IDEXX LABORATORIES INC (IDXX) stock?
ChartMill assigns a valuation rating of 4 / 10 to IDEXX LABORATORIES INC (IDXX). This can be considered as Fairly Valued.
Can you provide the profitability details for IDEXX LABORATORIES INC?
IDEXX LABORATORIES INC (IDXX) has a profitability rating of 9 / 10.
What are the PE and PB ratios of IDEXX LABORATORIES INC (IDXX) stock?
The Price/Earnings (PE) ratio for IDEXX LABORATORIES INC (IDXX) is 57.48 and the Price/Book (PB) ratio is 37.07.
What is the expected EPS growth for IDEXX LABORATORIES INC (IDXX) stock?
The Earnings per Share (EPS) of IDEXX LABORATORIES INC (IDXX) is expected to grow by 16.89% in the next year.